Mandolin

AI agents automating specialty-drug access workflows for infusion providers, pharmacies, and health systems.

Cover Block

From the public record

Field	Value
Name	Mandolin
Tagline	AI agents automating specialty-drug access workflows for infusion providers, pharmacies, and health systems [Business Wire, June 2025]
Headquarters	San Francisco [Crunchbase, retrieved 2026]
Founded	2024 [Crunchbase, retrieved 2026]
Stage	Series A [Crunchbase, retrieved 2026]
Business model	SaaS [Crunchbase, retrieved 2026]
Industry	Healthtech [Crunchbase, retrieved 2026]
Technology	AI / Machine Learning [Crunchbase, retrieved 2026]
Geography	North America [Crunchbase, retrieved 2026]
Growth profile	Venture Scale [Crunchbase, retrieved 2026]
Founding team	Co-Founders (2): Will Yin, Rohit Rustagi [Business Wire, June 2025]
Funding label	$10M+ [Business Wire, June 2025]
Total disclosed	$40,000,000 [Business Wire, June 2025]

The Short Version

PUBLIC Mandolin builds software that uses AI agents to automate the administrative path from specialty-drug referral to treatment authorization, a narrow but consequential workflow where delays directly affect provider capacity and patient access, and it merits investor attention now because it paired that pitch with a sizable June 2025 financing and unusually rapid reported clinic penetration [Mandolin, retrieved 2026] [Business Wire, June 2025] [HLTH, June 2025]. The company was founded in 2024 by Will Yin and Rohit Rustagi, a founding pair publicly identified as CEO and COO respectively, with outside profiles describing both as repeat entrepreneurs and Forbes later naming them to its 2026 30 Under 30 healthcare list [Business Wire, June 2025] [Citybiz, retrieved 2026] [Forbes, December 2025].

The product case is straightforward on paper: Mandolin says it runs intake, benefits verification, and prior authorization inside the provider's EHR or pharmacy system, while third-party coverage broadly describes the platform as automating specialty-drug access work for infusion providers, specialty pharmacies, and health systems [Mandolin, retrieved 2026] [Business Wire, June 2025] [MobiHealthNews, June 2025]. The point of differentiation, to the extent public evidence supports one, is focus rather than breadth, specifically the back-office handoffs around physician-administered specialty medicines, where Mandolin reported deployment across more than 700 clinic locations and service to over 250,000 new patients annually as of June 2025 [HLTH, June 2025] [Business Wire, June 2025] [Greylock, retrieved 2026].

The team story is promising but still only partly underwritten by public record. Will Yin's prior background includes a co-founder, president, and CTO role at Jupiter according to Crunchbase, while Rohit Rustagi's public profiles tie him to Alfie Health and Minimally Invasive Spinal Technology; that is relevant operating context, although the available sources do not establish major exits or long public tenure in specialty-drug workflow software [Crunchbase, retrieved 2026] [LinkedIn, retrieved 2026].

On capitalization, the clearest public fact is the June 2025 announcement of $40 million in combined seed and Series A funding, with Greylock leading the Series A and SignalFire identified as a seed lead, alongside a business model that is presented as software sold into provider and pharmacy operations [Business Wire, June 2025] [Crunchbase, retrieved 2026] [HealthTechAlpha, retrieved 2026]. Over the next 12 to 18 months, the key watchpoints are whether reported deployment breadth converts into durable enterprise depth, whether integrations and implementation remain tractable as customer count rises, and whether Mandolin can defend a workflow-specific position as both incumbents and newer AI entrants target the same specialty-access bottlenecks [Mandolin, retrieved 2026] [MobiHealthNews, June 2025] [Business Wire, June 2025].

Single-source, plausible -- This section relies on a mix of multi-source funding and scale reporting, plus product and team details that are partly company-described and partly corroborated by third-party coverage.

Taxonomy Snapshot

Axis	Value
Stage	Series A
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	$10M+ total disclosed, approximately $40,000,000 [Business Wire, June 2025]

The Company in Brief

PUBLIC

Mandolin enters the record first as a workflow company, not a research project: its homepage describes software that puts referral-to-authorization work on autopilot inside an EHR or pharmacy system, aimed at infusion providers, specialty pharmacies, and health systems [Mandolin, retrieved 2026]. Crunchbase lists the company as founded in 2024 and based in San Francisco [Crunchbase, retrieved 2026].

The chronology that can be supported from the requested source set is still short, but it is already useful. The company appears to have been formed in 2024, with Will Yin and Rohit Rustagi identified as co-founders in public company materials and database coverage [Mandolin, retrieved 2026] [Crunchbase, retrieved 2026]. By 2025, Mandolin had a public-facing product message centered on intake, benefits verification, and prior authorization embedded in existing clinical or pharmacy workflows, which is a narrower and more operational positioning than the broader "AI in healthcare" framing many peers adopt [Mandolin, retrieved 2026].

Crunchbase also records a June 2025 financing history that includes seed and Series A activity, aligning with the company's emergence from formation into scaled commercial rollout during its first full year in market [Crunchbase, retrieved 2026]. The legal entity name and state filing details were not established in the provided Crunchbase and company-site materials, so this section stays with the narrower facts the public record supports [Crunchbase, retrieved 2026] [Mandolin, retrieved 2026].

Single-source, plausible -- Confirmed with company website and Crunchbase; legal entity details were not corroborated from the requested source set.

What They Have Built

MIXED Mandolin is selling into one of the more operationally painful corners of healthcare administration, and the public record is fairly consistent on the core workflow it targets. On its homepage, the company says it puts "referral to authorization on autopilot" and runs intake, benefits verification, and prior authorization inside a customer's EHR or pharmacy system [Mandolin, retrieved 2026]. Press coverage and financing announcements describe the same wedge more broadly, framing Mandolin as an AI-agent platform for specialty-drug access workflows used by infusion providers, specialty pharmacies, and health systems [Business Wire, June 2025] [HLTH, June 2025] [MobiHealthNews, June 2025].

The scope beyond that initial intake-to-authorization motion is directionally supported, but the evidence is less even. Business Wire ties the platform to access for physician-administered therapies and says the company already supports more than 250,000 new patients per year across deployments at more than 700 clinic locations, which implies production use rather than pilot status [Business Wire, June 2025]. Separate third-party summaries describe the workflow surface as extending into scheduling and revenue-cycle work, and one press item characterizes the product as AI agents handling the paperwork between prescription and treatment, but those details are not laid out with the same precision on the company's own site [YesPress] [Seedtable] [Business Wire, June 2025].

What can be said with confidence is that Mandolin's differentiation claim rests on workflow execution inside existing clinical systems, not on a consumer-facing interface or a general-purpose medical chatbot. The website points to in-system operation within EHR or pharmacy software, while press accounts repeatedly position the product around automating insurer and provider administrative tasks required before specialty medication can be delivered [Mandolin, retrieved 2026] [HLTH, June 2025] [MobiHealthNews, June 2025]. Public materials do not verify the underlying model stack, implementation architecture, or integration method, so any deeper technical assessment would require product diligence rather than inference.

Single-source, plausible -- Grounded primarily in Mandolin's website and June 2025 financing coverage, with some workflow-scope details appearing in secondary summaries rather than direct company technical documentation.

Market Size and Demand

PUBLIC The market matters now because specialty-drug access has become a larger administrative bottleneck at the same time investors and providers are looking for software that can turn healthcare labor shortages into automation budgets, but the public record here is thinner on formal market sizing than on workflow pain points [Business Wire, June 2025] [MobiHealthNews, June 2025].

Mandolin is selling into a narrow operational layer rather than a broad "healthcare AI" abstraction. Public materials describe the product as software for intake, benefits verification, and prior authorization inside infusion, specialty-pharmacy, and health-system workflows, with an initial emphasis on physician-administered specialty medicines [Mandolin] [Business Wire, June 2025]. That framing implies a serviceable market defined by specialty-drug access operations, not all revenue-cycle management and not all clinical AI. No named third-party TAM, SAM, or SOM figure was captured in the research set, so any precise market estimate would overstate the evidence.

The clearer public signal is demand intensity. Mandolin reported deployment across more than 700 clinic locations and exposure to more than 250,000 new patients annually by June 2025, figures repeated across company announcement coverage and investor materials [Business Wire, June 2025] [HLTH, June 2025] [Greylock]. Even allowing for company-sourced inflation risk, those numbers suggest that access friction around specialty therapies is large enough for providers and pharmacies to trial workflow automation at meaningful scale. MobiHealthNews' coverage also tied the June 2025 financing to expansion in engineering and customer implementation, which is usually a sign that market demand is constrained less by category awareness than by deployment capacity [MobiHealthNews, June 2025].

The tailwinds are practical rather than thematic. Specialty drugs often require benefits verification and prior authorization before treatment begins, and Mandolin's own positioning rests on reducing the time between referral and therapy start [Mandolin] [Business Wire, June 2025]. That places the company in the path of several durable pressures: more complex reimbursement rules, provider staffing shortages, and rising willingness to fund administrative automation if it shortens time to treatment or reduces denied claims. Public sources do not quantify those pressures in this dataset, so the inference should stay modest, but the concentration of competitors around prior auth, specialty access, and adjacent healthcare workflow tooling points to a real budget line rather than a speculative one [Crunchbase, retrieved 2026] [Tracxn, retrieved 2026].

Adjacent markets matter because buyers may compare Mandolin against broader categories than the company initially targets. The nearest substitutes include revenue-cycle software, prior-authorization tooling, specialty-pharmacy operations software, and horizontal healthcare documentation or workflow automation products [Crunchbase, retrieved 2026] [Tracxn, retrieved 2026]. CoverMyMeds and SamaCare indicate an established access-workflow market on one side, while newer startups such as Asepha, Claimable, Develop Health, and Tandem suggest a newer wave of AI-first approaches on the other [Crunchbase, retrieved 2026] [Tracxn, retrieved 2026]. For Mandolin, that cuts both ways: the existence of incumbents validates budget availability, but it also means expansion beyond infusion and specialty access could require clearer proof that task-level automation outperforms generic revenue-cycle or healthcare AI tools.

Regulatory and macro exposure is central to the category, even if the available sources only show it indirectly. A business built around benefits verification and prior authorization sits downstream of payer policy, reimbursement complexity, and health-system compliance requirements, which means demand can rise when administrative rules grow more burdensome but product scope can also be shaped by integration, auditability, and trust expectations [Mandolin] [Business Wire, June 2025]. The homepage's emphasis on operating inside the EHR or pharmacy system and the site's SOC 2 Type II trust marker both fit that reading, though neither establishes regulatory clearance or a differentiated compliance moat on its own [Mandolin].

Market slice	Public evidence	Read-through
Specialty-drug access workflows	Mandolin positions itself around intake, benefits verification, and prior authorization for infusion providers, specialty pharmacies, and health systems [Mandolin]	Indicates a focused operational wedge rather than a broad clinical software market
Provider administrative automation	Reported use across 700+ clinic locations by June 2025 [Business Wire, June 2025] [HLTH, June 2025]	Suggests real buyer urgency around reducing manual access work
Specialty therapy onboarding volume	Reported service to 250,000+ new patients annually [Business Wire, June 2025] [Greylock]	Implies the workflow category touches high-throughput patient cohorts
Adjacent substitute categories	Competitor set spans access, prior auth, specialty workflow, and healthcare automation tools [Crunchbase, retrieved 2026] [Tracxn, retrieved 2026]	Buyers are likely benchmarking Mandolin against both incumbents and newer AI-first vendors

The table does not give a formal market size, but it does show where the evidence is strongest: this is a concrete workflow market with visible buyer pain and active vendor formation. The missing piece for investors is not whether the problem exists, it is how large the spend pool is within Mandolin's initial wedge and how defensible that wedge becomes as adjacent vendors converge.

Single-source, plausible -- Section relies on company and investor descriptions corroborated in named coverage, but no independent third-party market sizing report was captured in the public source set.

Who Else Is Fighting for This

MIXED Mandolin is entering a crowded but still fragmented part of healthcare administration, where the practical choice for buyers is less "AI versus no AI" than incumbent workflow software versus newer automation layers built around specialty-drug access [Mandolin, retrieved 2026] [Business Wire, June 2025].

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Mandolin	AI agents for specialty-drug access workflows at infusion providers, specialty pharmacies, and health systems	Series A, $40M disclosed in combined seed and Series A financing in June 2025	Reported deployment at 700+ clinic locations and workflow embedded inside EHR or pharmacy systems	[Business Wire, June 2025] [Mandolin, retrieved 2026] [HLTH, June 2025]
CoverMyMeds	Medication access and prior authorization platform	Not included in the structured facts	Established medication-access footprint with incumbent distribution in provider and pharmacy workflows	[Crunchbase, retrieved 2026]
SamaCare	Specialty medication access software	Not included in the structured facts	Focus on prior authorization and patient access for specialty therapies	[Crunchbase, retrieved 2026]
Claimable	Prior authorization automation software	Not included in the structured facts	Narrower automation focus centered on authorization workflows	[Crunchbase, retrieved 2026]
Asepha	Healthcare workflow automation company	Not included in the structured facts	Positioned around automation of administrative processes rather than a full specialty-access stack	[Crunchbase, retrieved 2026]

The field breaks into three groups. First are incumbents such as CoverMyMeds, which benefit from longstanding relationships across medication-access workflows and therefore enter most evaluations with buyer familiarity already in place [Crunchbase, retrieved 2026]. Second are specialty challengers such as SamaCare and Claimable, which appear closer to Mandolin's operating lane because they are built around prior authorization or specialty access rather than general healthcare IT [Crunchbase, retrieved 2026]. Third are adjacent substitutes, including broader administrative automation vendors such as Asepha and internal health-system operations teams that may try to automate parts of the process without replacing existing systems outright [Crunchbase, retrieved 2026].

Mandolin's edge, on the public record, is not scale of funding alone but a fairly specific workflow claim. The company says it runs intake, benefits verification, and prior authorization inside the EHR or pharmacy system, and it reported deployment across more than 700 clinic locations serving over 250,000 new patients annually as of June 2025 [Mandolin, retrieved 2026] [Business Wire, June 2025] [HLTH, June 2025]. If those deployments are sticky, the defensible asset is the task-level operating data generated in specialty-infusion and specialty-pharmacy workflows, because that kind of data can improve automation in ways a general administrative AI tool may struggle to match. That edge is still perishable, though, because the available evidence is company-linked reporting rather than independent renewal or outcome data, and rivals can pursue the same integration points if buyers remain open to swapping layers [Business Wire, June 2025] [Greylock, retrieved 2026].

The clearest exposure is distribution. CoverMyMeds has the advantage of incumbent presence, while narrower players like SamaCare or Claimable may win buyers that want a point solution for one painful step, especially prior authorization, rather than a broader platform sale [Crunchbase, retrieved 2026]. Mandolin also does not appear, from the public materials here, to own a proprietary channel such as a dominant payer network or a must-have pharmacy transaction rail. That matters because administrative software in healthcare often spreads through trusted workflow positions, not just better models or cleaner user experience [Mandolin, retrieved 2026] [Crunchbase, retrieved 2026].

The most plausible 18-month scenario is a sorting of the market by scope. Mandolin is the likely winner if provider groups continue preferring end-to-end automation across intake, benefits, authorization, and adjacent back-office work, because its public positioning is already broader than a single-step authorization tool and its reported clinic footprint gives it a reference base to build from [Mandolin, retrieved 2026] [Business Wire, June 2025]. Claimable is the likely winner if buyers narrow their budgets to a single, measurable pain point in prior authorization, where focused products can be easier to evaluate and implement [Crunchbase, retrieved 2026]. In that narrower-budget scenario, broader platforms that need multi-workflow adoption would be more exposed, and Mandolin would have to prove that the added scope produces operational savings quickly enough to justify the larger wedge.

Opportunity

PUBLIC The prize here is not a point solution for prior authorization, it is the chance to become the operating layer that sits between specialty-drug prescriptions and treatment across a large share of infusion providers, specialty pharmacies, and health systems in North America [Mandolin, retrieved 2026] [Business Wire, June 2025].

The headline opportunity is straightforward: if Mandolin can turn administrative specialty-drug access work into software-mediated workflow inside the systems clinicians already use, it can become default infrastructure for a painful, repeatable, high-value process rather than a narrow automation tool [Mandolin, retrieved 2026]. That outcome looks reachable, not merely aspirational, because the company says it already runs intake, benefits verification, and prior authorization inside the EHR or pharmacy system, and public reports place it across more than 700 clinic locations serving more than 250,000 new patients annually as of June 2025 [Mandolin, retrieved 2026] [Business Wire, June 2025] [HLTH, June 2025]. In healthtech, early breadth of deployment matters because workflow products tend to be sticky once embedded in revenue-critical operations; the evidence here does not prove durability yet, but it does show unusually fast early distribution for a company founded in 2024 [Crunchbase, retrieved 2026] [Business Wire, June 2025].

The upside paths branch from that same wedge: win the specialty clinic front office, broaden into adjacent reimbursement work, or become the integration layer partners standardize on.

Scenario	What happens	Catalyst	Why it's plausible
Embedded workflow standard	Mandolin becomes the default software layer for referral-to-authorization workflows across infusion centers, specialty pharmacies, and health systems	A major customer or partner rollout proves that running inside existing EHR or pharmacy systems can scale across multisite operations [Mandolin, retrieved 2026] [Business Wire, June 2025]	The company already positions the product as embedded inside customer systems, and reported deployment at 700+ clinic locations suggests the model travels beyond a pilot footprint [Mandolin, retrieved 2026] [HLTH, June 2025]
Expansion from access to revenue operations	Mandolin moves from intake and prior authorization into broader revenue-cycle and scheduling workflows tied to specialty therapies	Product expansion around the same patient journey, using the administrative foothold already described in public materials [Seedtable] [Business Wire, June 2025]	Public descriptions already span intake, benefits verification, prior authorization, scheduling, and revenue-cycle work, which implies adjacency rather than a new category bet [Mandolin, retrieved 2026] [Business Wire, June 2025]
Partner-led network distribution	Mandolin becomes the preferred administrative automation layer for named provider and pharmacy partners, creating a repeatable go-to-market through reference accounts	More named deployments among organizations similar to Vivo Infusion, TwelveStone Health Partners, and Amber Specialty Pharmacy [Business Wire, June 2025] [Fierce Healthcare, July 2025]	Publicly named customers and partners matter in a trust-sensitive healthcare workflow category, and the current list shows relevance across multiple care-delivery settings [Business Wire, June 2025]

The compounding mechanism, if it develops, is less about consumer-style network effects and more about workflow depth plus task-level learning. Mandolin says its agents run specific steps in specialty-drug access inside the systems staff already use, and outside coverage describes the company as focused on the administrative work between prescription and treatment rather than general-purpose clinical AI [Mandolin, retrieved 2026] [YesPress] [MobiHealthNews, June 2025]. If that is true in practice, each successful deployment should improve implementation playbooks, integration templates, and task performance on a narrow but recurring set of operational jobs. That can create a practical data moat around specialty-infusion administration, especially if customers trust the company with adjacent steps such as scheduling and revenue-cycle work after the initial prior-authorization wedge [Business Wire, June 2025] [Mandolin, retrieved 2026].

The size of the win is harder to pin down because no credible market-size dataset is provided in the available public materials, and there is no public valuation benchmark in the June 2025 financing disclosures [Business Wire, June 2025]. Even so, the scenario worth underwriting conceptually is clear: if Mandolin were to become a category leader in specialty-drug access infrastructure, the end state would resemble a scaled healthtech workflow platform with strategic value to payers, pharmacy platforms, revenue-cycle consolidators, or large health IT incumbents, rather than a small standalone tool (scenario, not a forecast). The public evidence supports that ambition only conditionally, but the combination of a reported $40 million combined seed and Series A, backing from Greylock and SignalFire, and a claimed 700-plus-clinic footprint gives the company enough early signal to treat the upside as a real possibility rather than a theoretical one [Business Wire, June 2025] [Crunchbase, retrieved 2026] [HLTH, June 2025].

Single-source, plausible -- This section relies on Mandolin's website and company-backed funding coverage, with partial corroboration from HLTH, MobiHealthNews, Fierce Healthcare, and Crunchbase.

Sources